Defense Supply Center Philadelphia, Attn: DSCP-M Bldg 9-4, 2800 S. 20th Street, Philadelphia, PA 19145-5099

65 -- ACQUISITION OF "HMG COA REDUCTASE INHIBITORS, COMMONLY KNOWN AS "STATINS" SOL SPO200-98-R-2503 POC William Di Lauro, telephone #1-215-737-8748 E-MAIL: Click here to contact the contracting officer via, wdilauro@dscp.dla.mil. The original notice is revised to read as follow: The Response Date for the solicitation will be 30 days from the date of issuance of the solicitation. Estimated date of issuance is 15 September 1998. The objective of the solicitation is to issue a minimum of one, maximum of two long-term National Contract(s) for "HMG-CoA Reductase Inhibitor" product group(s), commonly known as "Statins". The product group must be FDA approved as of the issuance date of the solicitation. At the time of issuance of this notice, the Defense Supply Center Philadelphia (DSCP) is aware of only the following Statins which meet the preceding requirement: atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin and simvastatin. The eventual awardee(s) will be required to furnish its product group to prime vendor distributors for use under DSCP's Pharmaceutical Prime Vendor and National Mail Order Pharmacy programs. -- -- -- -- -- - Prior to issuance of the solicitation, pharmaceutical companies are hereby invited, but not required, to make a presentation about the clinical attributes of their statins at the DoD Pharmacoeconomic Center, Fort Sam Houston, Texas between 18 August 1998 and 14 September 1998. One presentation will be permitted for each statin. Each presentation will be limited to no more than one hour. Companies may schedule their presentations by contacting MAJ Donald DeGroff at the DoD Pharmacoeconomic Center, telephone 210-295-9635 or 210-295-1271. Pharmaceutical companies are encouraged to provide the following information concerning their statins: (1) Point estimates of the average percentage reduction in low-density lipoprotein cholesterol (LDL-C) that would be achieved at each dosage for the statin and identification of the studies on which the point estimates are based. (2) Studies showing the effect that the statin has on the incidence of fatal and nonfatal myocardial infarctions. (3) A comparison of the statin to other statins regarding safety issues such as incidence of adverse effects and the incidence of clinically significant drug interactions. (4) Any other information pertaining to clinically significant differences between the statin and other statins. NOTE: The Government may use information provided during the presentations when drafting its solicitation. However, all awards will be based on the offers received in response to the actual solicitation and the evaluation criteria set forth therein. Posted 08/17/98 (W-SN237805). (0229)

Loren Data Corp. http://www.ld.com (SYN# 0342 19980819\65-0009.SOL)